glycoprotein Ab Measured in SGU and β 2- Diagnosis Supplemental IgG, IgM SMU, respectively Ceruloplasmin Measured in mg/dL Diagnosis/ Other Supplemental Measured in mg/dL (U.S.) Cholesterol - HDL*** Safety Supplemental or mmol/L (outside U.S.) Measured in mg/dL (U.S.) Cholesterol - LDL*** Safety Supplemental or mmol/L (outside U.S.) Measured in mg/dL (U.S.) Cholesterol, total Safety Supplemental or mmol/L (outside U.S.) Measured in mg/dL (U.S.) Cholesterol - VLDL Safety Supplemental or mmol/L (outside U.S.) C-reactive protein Measured in mg/L Diagnosis Supplemental (CRP) Creatinine Clearance Measured in mL/min Safety Supplemental Creatine Kinase - Measured in ng/mL Safety Supplemental Myocardial Bands Results reported as D-dimer positive, negative or not Safety Supplemental done Includes early antigen (EA), VCA IgG, IgM, and Epstein-Barr virus EBNA. Results reported Diagnosis/ Other Supplemental (EBV) panel as positive, negative or not done. Erythrocyte Measured in mm/hr Diagnosis Supplemental Sedimentation Rate Results reported as Factor V Leiden negative, heterozygous, or Diagnosis Supplemental Mutation homozygous Fibrinogen Measured in mg/dL Safety Supplemental Folate, serum level Measured in ng/mL Diagnosis Supplemental Intentionally left GAD 65 Ab Intentionally left blank Intentionally left blank blank Sample ranges: estimated creatinine clearance – normal 90+; mild 60-89; Glomerular Filtration moderate 30-59; Safety Supplemental Rate (eGFR) <15ml/min = kidney failure; measured in mL/min; required if study uses MRI with contrast Results indicate "average" Glycosylated blood sugar over 6-12 Diagnosis Supplemental hemoglobin (HbA1c) week time; sample normal is 4%-6%; measured in % Acute phase reactant elevated with High sensitivity C inflammation; non-specific; Diagnosis Supplemental Reactive Protein not clear, usually is <10.0; measured in mg/L
β 2- glycoprotein Ab IgG, IgM Measured in SGU and SMU, respectively Diagnosis Supplemental Ceruloplasmin Measured in mg/dL Diagnosis/ Other Supplemental Cholesterol - HDL*** Measured in mg/dL (U.S.) or mmol/L (outside U.S.) Safety Supplemental Cholesterol - LDL*** Measured in mg/dL (U.S.) or mmol/L (outside U.S.) Safety Supplemental Cholesterol, total Measured in mg/dL (U.S.) or mmol/L (outside U.S.) Safety Supplemental Cholesterol - VLDL Measured in mg/dL (U.S.) or mmol/L (outside U.S.) Safety Supplemental C-reactive protein (CRP) Measured in mg/L Diagnosis Supplemental Creatinine Clearance Measured in mL/min Safety Supplemental Creatine Kinase - Myocardial Bands Measured in ng/mL Safety Supplemental D-dimer Results reported as positive, negative or not done Safety Supplemental Epstein-Barr virus (EBV) panel Includes early antigen (EA), VCA IgG, IgM, and EBNA. Results reported as positive, negative or not done. Diagnosis/ Other Supplemental Erythrocyte Sedimentation Rate Measured in mm/hr Diagnosis Supplemental Factor V Leiden Mutation Results reported as negative, heterozygous, or homozygous Diagnosis Supplemental Fibrinogen Measured in mg/dL Safety Supplemental Folate, serum level Measured in ng/mL Diagnosis Supplemental GAD 65 Ab Intentionally left blank Intentionally left blank Intentionally left blank Glomerular Filtration Rate (eGFR) Sample ranges: estimated creatinine clearance – normal 90+; mild 60-89; moderate 30-59; <15ml/min = kidney failure; measured in mL/min; required if study uses MRI with contrast Safety Supplemental Glycosylated hemoglobin (HbA1c) Results indicate "average" blood sugar over 6-12 week time; sample normal is 4%-6%; measured in % Diagnosis Supplemental High sensitivity C Reactive Protein Acute phase reactant elevated with inflammation; non-specific; not clear, usually is <10.0; measured in mg/L Diagnosis Supplemental
F1287_Laboratory_Test_Recommendations.docx